Upadacitinib
Records for this ingredient, by country (identity only).
ATC L04AF03 · 9 markets · 28 records
JP 5 records · 5 shown of 5
- 45 mgtabletリンヴォック錠45mg
- 30 mgtabletリンヴォック錠45mg
- 15 mgtabletリンヴォック錠45mg
- 7.5 mgtabletリンヴォック錠45mg
- 180 mg/180 mLotherリンヴォック内用液0.1%(1mg/mL)
US 4 records · 4 shown of 4
GB 3 records · 3 shown of 3
- 45 mgtablet · extended-releaseRinvoq 15mg modified-release tablets
- 30 mgtablet · extended-releaseRinvoq 15mg modified-release tablets
- 15 mgtablet · extended-releaseRinvoq 15mg modified-release tablets
CA 3 records · 3 shown of 3
AU 3 records · 3 shown of 3
ES 3 records · 3 shown of 3
HK 3 records · 0 shown of 0
3 records · 0 manufacturers 3 registros · 0 fabricantes 3 个记录 · 0 个厂家 3 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
EU 1 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.
| Strength / form / release | US | GB | CA | AU | ES | HK | JP | EU |
|---|---|---|---|---|---|---|---|---|
| 45 mg tablet · extended-release | Rinvoq | Rinvoq 15mg modified-release tablets | Rinvoq | Rinvoq | Rinvoq | |||
| 30 mg tablet · extended-release | Rinvoq | Rinvoq 15mg modified-release tablets | Rinvoq | Rinvoq | Rinvoq | |||
| 15 mg tablet · extended-release | Rinvoq | Rinvoq 15mg modified-release tablets | Rinvoq | Rinvoq | Rinvoq | |||
| 45 mg tablet | リンヴォック錠45mg | |||||||
| 30 mg tablet | リンヴォック錠45mg | |||||||
| 15 mg tablet | リンヴォック錠45mg | |||||||
| 7.5 mg tablet | リンヴォック錠45mg | |||||||
| 1 mg per mL / per unit basis not stated cannot compare liquid | Rinvoq | |||||||
| 180 mg/180 mL other | リンヴォック内用液0.1%(1mg/mL) | |||||||
unknown | RINVOQ PROLONGED-RELEASE TABLETS 15MG | Rinvoq |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
1 more strength/form rows are recorded only in HK · EU and are not shown in this table. Hay 1 filas de concentración/forma registradas solo en HK · EU que no se muestran en esta tabla. 另有 1 个规格/剂型仅在 HK · EU 有记录（未在本表显示）。 另有 1 個規格/劑型僅在 HK · EU 有記錄（未在本表顯示）。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.